The Increasing PV Obligations of Scientific Literature

Scientific literature is a significant source of information for the monitoring of the safety profile of medicinal products, particularly in relation to the detection of new safety signals or emerging safety issues.

With global regulations constantly shifting and with the level of scientific literature progressively increasing, pharmacovigilance teams are under continued pressure to create literature strategies that are both comprehensive and flexible. Therefore, establishing the right process from the outset is fundamental to ensure that compliance deliverables are met.

5 points to consider when developing a literature review process:

1. Where to look for scientific literature?

The type of medicinal product (drug, medical device) should determine what type of database to use however, most well-known databases such as Medline or Embase cover most scientific and medical journals.

2. How to develop a scientific literature strategy?

Author abstracts are not always consistent in the choice of words relating to pharmacovigilance concepts thus, applying a search strategy will help to eliminate background noise, giving focus to scientific publications that are most relevant to pharmacovigilance. It is important to know your product and what you are trying to achieve; the highest recall for a search would be to enter the medicinal product name and active substance name (in all their variants) only. In practice, additional text can be added to increase precision. It is always good practice to retain a record of the search construction, the database used and the date the search was run.


Would you like to learn more about our pharmacovigilance services?

About the author
Natasha Daly
Pharmacovigilance Manager
Natasha joined Acorn Regulatory in October 2018 as Pharmacovigilance Manager. Natasha has over 11 years’ experience in the pharmaceutical industry. Her experience comes from working in a large global innovator pharmaceutical company and a large global generic company and includes drug development, post-marketing and clinical trials. Natasha`s role as pharmacovigilance manager at Acorn Regulatory is intended to ensure that the procedures in place are adhered to and that Acorn Regulatory provides a quality of service to its clients acceptable to any inspecting authority. You can read more articles by Natasha Daly clicking the link below.
Other articles by Natasha Daly